Login to Your Account



Also, FDA Widens Byetta Net

Early Stage Obesity Deal Nets Amylin $1.075B from Takeda

By Catherine Hollingsworth


Tuesday, November 3, 2009
Amylin Pharmaceuticals Inc. got a double dose of good news Monday, signing a $1 billion-plus deal to co-develop obesity compounds with Japanese partner Takeda Pharmaceutical Co. Ltd., and getting FDA approval for expanded use of diabetes drug Byetta as a first-line therapy. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription